martes, 2 de abril de 2019

Rubius hails preclinical data on red blood cell-derived cancer drugs - STAT

Rubius hails preclinical data on red blood cell-derived cancer drugs - STAT

Cancer Briefing

STAT Plus: It’s only test tubes and mice, but Rubius Therapeutics hails first new data on red blood cell-derived cancer drugs

By ADAM FEUERSTEIN


RUBY WALLAU FOR STAT
The results come from test tubes and mice, but Rubius says they show that genetically augmenting red blood cells to stimulate the immune system is possible.

No hay comentarios: